Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823039 | 0.85 | — | — | |
| SCHEMBL25823043 | 0.84 | DGAT1 (0.44) | NPC1RAB9ASMN1; SMN2DGAT1 | |
| SCHEMBL25824388 | 0.80 | NPC1 (0.36) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25823019 | 0.80 | SMN1; SMN2 (0.49) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25823026 | 0.78 | P2RX7 (0.38) | CYP11B1CYP11B2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25824923 | 0.78 | IRAK4 (0.31) | — | |
| SCHEMBL25823060 | 0.78 | CHRNB4 (0.33) | — | |
| SCHEMBL25823035 | 0.78 | CYP11B2 (0.35) | CYP11B1CYP11B2CYP19A1CYP2C9 | |
| SCHEMBL25823010 | 0.77 | CYP2E1 (0.36) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25823015 | 0.74 | CCNA2 (0.38) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NPC1 3864/4885RAB9A 2922/4885CYP11B1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.